Advanced Endometrial Carcinoma research hub
3 indexed studies · 0 currently recruiting
- active not recruitingPHASE2
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
This study looks at new treatments for advanced endometrial cancer that has come back or spread. It tests if combining two drugs, cabozantinib and nivolumab, works better than nivolumab alone to shrink cancer and help people live longer. This could offer new hope for patients.
United States · Canada - active not recruitingPHASE2
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This study is testing different combinations of new drugs (olaparib, durvalumab, capivasertib, and cediranib) for recurrent or hard-to-treat womb cancer. The aim is to find out if these combinations can stop the cancer from growing or spreading more effectively.
United States · Canada - active not recruitingPHASE3
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
This study is testing if adding an immunotherapy drug called pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) works better for advanced or returning womb cancer. It aims to see if this new combination helps patients more than chemotherapy alone.
United States · Canada · Japan